Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$63.22 USD

63.22
151,890

-0.28 (-0.44%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $63.23 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New Strong Sell Stocks for July 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

New Strong Sell Stocks for March 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag Estimates

ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

4 Drug/Biotech Outperformers That May Lose Steam in 2020

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

New Strong Sell Stocks for December 4th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Moving Average Crossover Alert: ANI Pharmaceuticals

ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Shrabana Mukherjee headshot

5 Stocks to Consider as New Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes ANI (ANIP) a New Buy Stock

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

Tirthankar Chakraborty headshot

American Economy Hits the Gas: 5 Top Gainers

The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day.

Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised

Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide